

Product Data Sheet

Venadaparib hydrochloride

 Cat. No.:
 HY-137457A

 CAS No.:
 1681020-60-9

 Molecular Formula:
 C23H24ClFN4O2

Molecular Weight: 442.91
Target: PARP

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Venadaparib (IDX-1197) hydrochloride is a potent and selective PARP inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research $^{[1][2]}$.	
IC ₅₀ & Target	PARP1 1.4 nM (IC ₅₀)	PARP2 1 nM (IC ₅₀)
In Vitro	Venadaparib (example 143; 6-10 days) shows potent growth inhibition of MDA-MB-436 cells and Capan-1 pancreatic cancer cells with IC ₅₀ values of ≤5nM and 50nM [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	In the germline BRCA1-mutated ovarian cancer PDX model, oral administration of Venadaparib (IDX-1197) exhibits significant PAR inhibition (>90%) in tumor tissues until 24 hr post dose. Venadaparib also dose-dependently led to potent tumor growth inhibition compared to Olaparib treatment group ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107.

[2]. Jae-Hoon Kang, et al. A novel phtalazinone derivatives and manufacturing process thereof. WO2015037939A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA